metoprolol has been researched along with Muscular Dystrophy, Duchenne in 4 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
Excerpt | Relevance | Reference |
---|---|---|
" Secondary: changes of a) LV-FS from baseline, b) blood pressure, c), heart rate and autonomic function in ECG and Holter-ECG, e) cardiac biomarkers and neurohumeral serum parameters, f) quality of life, and g) adverse events." | 6.90 | Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial. ( Dittrich, S; Ebinger, F; Graf, E; Heilmann, A; Khalil, M; Kirschner, J; Korenke, C; Lange, M; Motz, R; Müller-Felber, W; Neudorf, U; Pattathu, J; Pozza, RD; Schara, U; Schröder, R; Stiller, B; Trollmann, R; von Au, K; von der Hagen, M; Weiss, K; Wiechmann, N; Wilichowski, E, 2019) |
" Secondary: changes of a) LV-FS from baseline, b) blood pressure, c), heart rate and autonomic function in ECG and Holter-ECG, e) cardiac biomarkers and neurohumeral serum parameters, f) quality of life, and g) adverse events." | 2.90 | Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial. ( Dittrich, S; Ebinger, F; Graf, E; Heilmann, A; Khalil, M; Kirschner, J; Korenke, C; Lange, M; Motz, R; Müller-Felber, W; Neudorf, U; Pattathu, J; Pozza, RD; Schara, U; Schröder, R; Stiller, B; Trollmann, R; von Au, K; von der Hagen, M; Weiss, K; Wiechmann, N; Wilichowski, E, 2019) |
"Most patients with Duchenne muscular dystrophy (DMD) will develop cardiomyopathy; however, the evidence for prophylactic treatment of children with cardiac medications is limited." | 1.42 | Absence of Cardiac Benefit with Early Combination ACE Inhibitor and Beta Blocker Treatment in mdx Mice. ( Blain, A; Blamire, AM; Greally, E; Laval, SH; MacGowan, GA; Straub, VW, 2015) |
"Metoprolol was given orally (2." | 1.36 | Intolerance to ß-blockade in a mouse model of δ-sarcoglycan-deficient muscular dystrophy cardiomyopathy. ( Bauer, R; Blain, A; Bushby, K; Greally, E; Laval, S; Lochmüller, H; MacGowan, GA; Straub, V, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Razzoli, M | 1 |
Lindsay, A | 1 |
Law, ML | 1 |
Chamberlain, CM | 1 |
Southern, WM | 1 |
Berg, M | 1 |
Osborn, J | 1 |
Engeland, WC | 1 |
Metzger, JM | 1 |
Ervasti, JM | 1 |
Bartolomucci, A | 1 |
Dittrich, S | 1 |
Graf, E | 1 |
Trollmann, R | 1 |
Neudorf, U | 1 |
Schara, U | 1 |
Heilmann, A | 1 |
von der Hagen, M | 1 |
Stiller, B | 1 |
Kirschner, J | 1 |
Pozza, RD | 1 |
Müller-Felber, W | 1 |
Weiss, K | 1 |
von Au, K | 1 |
Khalil, M | 1 |
Motz, R | 1 |
Korenke, C | 1 |
Lange, M | 1 |
Wilichowski, E | 1 |
Pattathu, J | 1 |
Ebinger, F | 1 |
Wiechmann, N | 1 |
Schröder, R | 1 |
Blain, A | 2 |
Greally, E | 2 |
Laval, SH | 1 |
Blamire, AM | 1 |
MacGowan, GA | 2 |
Straub, VW | 1 |
Bauer, R | 1 |
Bushby, K | 1 |
Lochmüller, H | 1 |
Laval, S | 1 |
Straub, V | 1 |
1 trial available for metoprolol and Muscular Dystrophy, Duchenne
Article | Year |
---|---|
Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardio | 2019 |
3 other studies available for metoprolol and Muscular Dystrophy, Duchenne
Article | Year |
---|---|
Social stress is lethal in the mdx model of Duchenne muscular dystrophy.
Topics: Adrenergic beta-Antagonists; Animals; Arterial Pressure; Disease Models, Animal; Dystrophin; Gait Di | 2020 |
Absence of Cardiac Benefit with Early Combination ACE Inhibitor and Beta Blocker Treatment in mdx Mice.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium; Captopril; | 2015 |
Intolerance to ß-blockade in a mouse model of δ-sarcoglycan-deficient muscular dystrophy cardiomyopathy.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-1 Receptor Antagonists; Animals; Disease Models | 2010 |